Vivani is a clinical-stage biopharmaceutical company developing miniature subdermal drug implants for chronic diseases, focused on GLP-1 therapies for obesity and type 2 diabetes. Vivani's core insight is that medication non-adherence is a major barrier to GLP-1 therapy — roughly 64% of patients on Wegovy discontinue within the first year — and that a long-acting implant can effectively solve this by delivering continuous drug exposure for six months or longer without patient action. The implant is inserted during a routine office visit and can be removed at any time, stopping therapy immediately. Vivani's proprietary NanoPortal platform uses a titanium-oxide nanoporous membrane with precisely sized nanotubes to enable near-constant drug release with no moving parts. Vivani's lead candidate, NPM-139, is a semaglutide implant targeting obesity, with Phase 1 trials expected to begin in mid-2026. NPM-133 is a similar semaglutide implant for type 2 diabetes, and NPM-115 is an exenatide implant for obesity that completed a Phase 1 study in 2025. A fourth program, OKV-119, is an exenatide implant for companion animals developed in partnership with Okava Pharmaceuticals. Vivani has no products on the market and generates no product revenue, funding operations through equity financing. The long-term business model involves either licensing candidates to large pharma partners or independently commercializing closer to approval.